2020版肺癌多学科团队诊疗中国专家共识解读

肺癌是一类异质性较高的恶性肿瘤，诊疗有争议、预后不确定的现象屡见不鲜。目前，肺癌的管理呈现个性化、精准化、多学科、综合治疗的发展趋势。基于循证医学的多学科团队（multidisciplinary team，MDT）诊疗融合了最佳证据、专家经验和个人意愿，减少专科医生的选择偏倚，强调对患者诊疗决策的改变，可有效提高患者的临床获益，优化医疗资源使用，提升诊疗的合理性，拓展科研思路，最终使医患双方在多方面获益。为规范中国肺癌MDT诊疗的开展，中国胸部肿瘤研究协作组、中国抗癌协会肺癌专业委员会、中华医学会肿瘤学分会肺癌学组和中国医师协会肿瘤多学科诊疗专业委员会于2020年共同制定了《肺癌多学科团队诊疗中国专家共识》。本文将从MDT的准备、实施、后期、实战应用4个方面对该共识进行解读。 

Interpretation of Chinese expert consensus on multidisciplinary team diagnosis and treatment of lung cancer (2020 version)

Lung cancer is a type of malignant tumor with high heterogeneity and presents with controversial diagnosis, uncertain prognosis, and debated forms of treatment. Currently, lung cancer management shows a developmental trend of personalized, precise, multidisciplinary, and comprehensive treatment. Based on evidence-based medicine, multidisciplinary teams (MDT) integrate the best evidence, expert experience, and patient wishes, which reduces bias in the selection of specialists and emphasizes changes in diagnosis and treatment decisions for patients. MDT can effectively improve clinical benefits in patients, optimize the use of medical resources, improve the rationality of diagnosis and treatment, introduce new ideas from scientific research, and finally benefit both doctors and patients in many ways. To standardize the development of MDT diagnosis and treatment of lung cancer in China, members of the Chinese Thoracic Oncology Group; Chinese Society of Lung Cancer; Lung Cancer Group of Oncology Branch, Chinese Medical Association; and the Multidisciplinary Team Diagnosis and Treatment Committee, Chinese Medical Doctor Association jointly published a Chinese expert consensus on multidisciplinary team diagnosis and treatment of lung cancer. This article interprets the consensus in reference to four perspectives: MDT preparation, implementation, later stage, and practical application.